• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 5 filed by Sheridan Gareth

    11/25/25 5:12:40 PM ET
    $NTRB
    Industrial Specialties
    Health Care
    Get the next $NTRB alert in real time by email
    SEC FORM 5 SEC Form 5
    FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0362
    Estimated average burden
    hours per response: 1.0
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Form 3 Holdings Reported.
    X
    Form 4 Transactions Reported.
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Sheridan Gareth

    (Last) (First) (Middle)
    C/O NUTRIBAND INC.
    121 S. ORANGE AVE, SUITE 1500

    (Street)
    ORLANDO FL 32801

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NutriBand Inc. [ NTRB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)
    01/31/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Amount (A) or (D) Price
    Common Stock 3 1,761,667 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $2.61 03/20/2024 4A 97,500 03/20/2024 03/20/2027 Common Stock 97,500 $2.61 251,000 D
    Stock Option $8.07 01/29/2025 4A 29,333 01/29/2025 01/29/2028 Common Stock 29,333 $8.07 251,000 D
    Explanation of Responses:
    /s/ Gareth Sheridan 11/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NTRB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRB

    DatePrice TargetRatingAnalyst
    1/22/2025$13.00Outperform
    Noble Capital Markets
    More analyst ratings

    $NTRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Nutriband with a new price target

    Noble Capital Markets initiated coverage of Nutriband with a rating of Outperform and set a new price target of $13.00

    1/22/25 9:24:55 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

    ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent technologies, today announced the signing of a non-binding Letter of Intent ("LOI") with the Qvanta Group of Companies. The Qvanta Group comprises Qvanta LLC and its subsidiaries, Qvanta Foundry LLC and Qvanta Capital LLC (collectively, "Qvanta"). Qvanta is a U.S.-based advanced technology organization developing the BigΔx Quantum Defense Fabric, an integrated quantum-AI cybersecurity and computing platform designed to support enterprise, government, and high-security research environments.

    12/18/25 8:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

    Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. Illicit fentanyl and its core precursor chemicals have been designated as weapons of mass destruction to enable the US government to combat the manufacture and distribution by cartels and foreign networks that have flooded the US with illegal fentanyl. Nutriband is developing Aversa™ Fentanyl, an abuse deterrent fentanyl transdermal system, which combines Nutriband's proprietary Aversa™ abuse-deterrent technology with Kindeva's FDA-approv

    12/18/25 7:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

    Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent transdermal system) through commercialization. Nutriband received final meeting minutes from FDA and is incorporating the feedback into the development program as it moves forward to an IND filing in support of a Human Abuse Potential (HAP) clinical study for the product. ORLANDO, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received final meeting minutes from its recent virtual face-to-face meeting

    10/28/25 11:05:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    SEC Filings

    View All

    SEC Form DEF 14A filed by Nutriband Inc.

    DEF 14A - NutriBand Inc. (0001676047) (Filer)

    12/19/25 11:01:52 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NutriBand Inc. (0001676047) (Filer)

    10/28/25 12:00:00 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Nutriband Inc.

    10-Q - NutriBand Inc. (0001676047) (Filer)

    9/9/25 5:27:40 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 5 filed by Sheridan Gareth

    5 - NutriBand Inc. (0001676047) (Issuer)

    11/25/25 5:12:40 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    Goodman Gerald exercised 60,085 in-the-money shares at a strike of $1.93, increasing direct ownership by 1,001% to 66,085 units (SEC Form 5)

    5 - NutriBand Inc. (0001676047) (Issuer)

    10/21/25 1:50:53 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Financial Officer Goodman Gerald

    4 - NutriBand Inc. (0001676047) (Issuer)

    12/2/24 3:49:25 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nutriband Inc.

    SC 13D/A - NutriBand Inc. (0001676047) (Subject)

    9/19/24 11:38:15 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Nutriband Inc.

    SC 13G - NutriBand Inc. (0001676047) (Subject)

    2/13/24 8:33:52 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Nutriband Inc.

    SC 13G - NutriBand Inc. (0001676047) (Subject)

    2/12/24 3:57:44 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Leadership Updates

    Live Leadership Updates

    View All

    Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

    ORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (the "Company") is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025. The next Emerging Growth Conference is presenting on August 20, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman, Serguei Melnik in real time. Mr. Melnik will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. Melnik will do his best to

    8/18/25 9:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

    The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri

    5/16/24 7:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Financials

    Live finance-specific insights

    View All

    Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

    ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August. 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an ann

    7/18/25 9:15:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

    ORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 25% preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual bas

    7/2/25 8:05:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo

    5/10/24 9:00:00 AM ET
    $CANF
    $NTRB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties